A doctor at the centre of a review of the treatment of more than 200 patients with lung disease is being investigated by the ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

More than 200 patients have had their lung disease treatment reviewed following concerns their care at a Surrey hospital did ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.

In this article, we take a look at five biotech companies developing potentially transformative medicines to treat cystic ...

Other causes of lung cancer are well known, like radon gas exposure, which happens to be fairly prevalent in Appalachia. It’s ...

Overall, the collective findings from this Phase 1b clinical trial provide the Company with strong confidence that LTI-03 has ...

Associate professor Satoshi Watanabe and his teams from Niigata University have revealed that PET/CT image analysis using ...